title: [Hormonal treatment in prostate cancer].
abstract: OBJECTIVE
  To describe drugs used in the hormonal treatment (hormonotherapy) of prostate cancer.
  
  
  METHODS
  Bibliographical search was performed from the database Medline (National Library of Medicine, PubMed) and websites of the HAS and the ANSM. The search was focused on the characteristics, the mode of action, the efficiency and the side effects of the various drugs concerned.
  
  
  RESULTS
  LHRH analogs and the antiandrogens remain the cornerstone in the treatment of locally advanced and metastatic prostate cancer. New therapeutic classes emerged recently (inhibitor of the synthesis of the androgen, the new antiandrogens) and allowed to grow again the limits of the hormone resistance and define the concept castration-resistant prostate cancer.
  
  
  CONCLUSIONS
  The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part.
authors.affiliation: Service d'urologie, hôpital Nord, AP-HM, Aix-Marseille université, 13015 Marseille, France. Electronic address: cyrille.bastide@ap-hm.fr.
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.forename: F
authors.initials: F
authors.lastname: Bruyère
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: F
authors.initials: F
authors.lastname: Rozet
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D059002:Androgen Receptor Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001549:Benzamides; D003131:Combined Modality Therapy; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D006801:Humans; D048289:Imidazolidines / Q000627:therapeutic use; D008297:Male; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D009570:Nitriles; D009842:Oligopeptides / Q000627:therapeutic use; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D004968:Estrogens, Non-Steroidal; D048289:Imidazolidines; D009570:Nitriles; D009842:Oligopeptides; C431566:acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; D010669:Phenylthiohydantoin; D007987:Gonadotropin-Releasing Hormone; D004961:Estramustine; D017373:Cyproterone Acetate; C021277:nilutamide; D004054:Diethylstilbestrol; D005485:Flutamide; C540278:enzalutamide
keywords: Abiraterone acetate; Acétate d’abiratérone; Analogues de la LHRH; Anti-androgènes; Antiandrogens; Cancer de la prostate; Degarelix; Diethylstilbestrol; Diéthylstilbestrol; Dégarélix; Enzalutamid; Enzalutamide; Estramustin; Estramustine; Hormonal treatment; LHRH analogs; Prostate cancer; Traitement hormonal